000117384 001__ 117384 000117384 005__ 20230519145548.0 000117384 0247_ $$2doi$$a10.1016/j.bcp.2021.114655 000117384 0248_ $$2sideral$$a127078 000117384 037__ $$aART-2021-127078 000117384 041__ $$aeng 000117384 100__ $$aSerrano-del Valle A. 000117384 245__ $$aFuture prospects for mitosis-targeted antitumor therapies 000117384 260__ $$c2021 000117384 5060_ $$aAccess copy available to the general public$$fUnrestricted 000117384 5203_ $$aDysregulation of cell cycle progression is a hallmark of cancer cells. In recent years, efforts have been devoted to the development of new therapies that target proteins involved in cell cycle regulation and mitosis. Novel targeted antimitotic drugs include inhibitors of aurora kinase family, polo-like kinase 1, Mps1, Eg5, CENP-5 and the APC/cyclosome complex. While certain new inhibitors reached the clinical trial stage, most were discontinued due to negative results. However, these therapies should not be readily dismissed. Based on recent advances concerning their mechanisms of action, new strategies could be devised to increase their efficacy and promote further clinical trials. Here we discuss three main lines of action to empower these therapeutic approaches: increasing cell death signals during mitotic arrest, targeting senescent cells and facilitating antitumor immune response through immunogenic cell death (ICD). © 2021 The Author(s) 000117384 536__ $$9info:eu-repo/grantAgreement/ES/MINECO/SAF2016-76338-R 000117384 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/ 000117384 590__ $$a6.1$$b2021 000117384 592__ $$a1.24$$b2021 000117384 594__ $$a9.3$$b2021 000117384 591__ $$aPHARMACOLOGY & PHARMACY$$b46 / 279 = 0.165$$c2021$$dQ1$$eT1 000117384 593__ $$aPharmacology$$c2021$$dQ1 000117384 593__ $$aBiochemistry$$c2021$$dQ1 000117384 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion 000117384 700__ $$aReina-Ortiz C. 000117384 700__ $$aBenedi A.$$uUniversidad de Zaragoza 000117384 700__ $$0(orcid)0000-0002-5175-8394$$aAnel A.$$uUniversidad de Zaragoza 000117384 700__ $$0(orcid)0000-0003-2156-8378$$aNaval J.$$uUniversidad de Zaragoza 000117384 700__ $$0(orcid)0000-0002-2315-9079$$aMarzo I.$$uUniversidad de Zaragoza 000117384 7102_ $$11002$$2060$$aUniversidad de Zaragoza$$bDpto. Bioq.Biolog.Mol. Celular$$cÁrea Bioquímica y Biolog.Mole. 000117384 7102_ $$11002$$2050$$aUniversidad de Zaragoza$$bDpto. Bioq.Biolog.Mol. Celular$$cÁrea Biología Celular 000117384 773__ $$g190 (2021), 114655 [13 pp]$$pBiochem. pharmacol.$$tBiochemical Pharmacology$$x0006-2952 000117384 8564_ $$s4109241$$uhttps://zaguan.unizar.es/record/117384/files/texto_completo.pdf$$yVersión publicada 000117384 8564_ $$s2631197$$uhttps://zaguan.unizar.es/record/117384/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000117384 909CO $$ooai:zaguan.unizar.es:117384$$particulos$$pdriver 000117384 951__ $$a2023-05-18-15:46:56 000117384 980__ $$aARTICLE